Trevena

Trevena, Inc. (Nasdaq: TRVN), headquartered in Chesterbrook, PA, is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

Finance

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024November 8, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) released its financial results for the third quarter ending September 30, 2024, revealing significant corporate changes as the company navigates ongoing financial challenges. …

Public Companies

Trevena, Inc. Faces Delisting from Nasdaq

October 5, 2024October 5, 2024 - by Timothy Alexander

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced that its common stock is set to be delisted from The Nasdaq Stock Market LLC following a decision by the Nasdaq Hearings Panel …